Monopar Therapeutics Inc.
Healthcare · EUR · F
Price
€46.634
Cap
€425.87M
Earnings
—
30d Trend
+2.2%
65% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 42×Macro 0.99 (−1%)=42
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 80%
BRAIN47 HORIZON ANALYSIS
Limited short-term thesis
BRAIN47'S ASSESSMENT
I rate Monopar Therapeutics Inc. at 42/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is technical at 60/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
+28.6%
3 MONTHS
+17.6%
12 MONTHS
+98.9%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Limited short-term thesis. Technical (60) and Momentum (54) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 65%. I classify this as a speculative position — elevated volatility at 65% and smaller market cap define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.